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CONCLUSIONS: This exploratory analysis suggests that use of a broader range of
metrics to assess and benchmark value across tumor types may be needed to
appropriately inform decision-makers looking to maximize clinical benefit to pa-
tients while managing constrained resources.
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SAMPLE SIZE ESTIMATION FOR PROSPECTIVE OBSERVATIONAL STUDIES
Cox TA1, Gemmen E1, Nixon M2, Doyle J3, Burgess AJ2, Jo H1, Kamble S1
1Quintiles, Rockville, MD, USA, 2Quintiles, Bracknell, Berkshire, UK, 3Quintiles, Hawthorne, NY,
USA
OBJECTIVES: Unlike randomized clinical trials (RCTs), prospective observational
studies typically address objectives rather than test specific hypotheses. Neverthe-
less, a minimum sample size is required to allow for adequate exploration of the
objectives, and estimation of sample size is an important part of the planning
process for these studies. Sample size estimation for observational studies is more
complex than sample size calculation for RCTs; subgroup analyses and modeling
are to be expected in observational studies, and these analysis methods may re-
quire more assumptions and larger sample sizes. At the same time, sample sizes
must not be so large as to raise concern that the study includes an unnecessarily
high number of sites and patients. This is particularly true for product registries
where a specific product is being observed. METHODS: This poster will provide
examples/case studies of sample size estimations performed for a variety of pro-
spective observational studies and objectives. These case studies will focus on the
following METHODS: 1) Incorporation of planned propensity score matching to
support comparisons of cohorts or subgroups; 2) Investigation of factors that influ-
ence outcomes within subgroups; 3) Estimation expressed as number of person-
years rather than persons; and 4) Re-estimation of sample size based on interim
results. RESULTS AND CONCLUSIONS: These methods illustrate the difference
between sample size estimation in prospective observational studies and sample
size calculation in randomized clinical trials.
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THE IMPACT OF CENTRE SELECTION ON THE GENERALISABILITY OF ECONOMIC
EVALUATION RESULTS FROM MULTI-CENTRE RANDOMISED CONTROLLED
TRIALS
Gheorghe A, Roberts TE, Calvert M, Wilson S
University of Birmingham, Birmingham, UK
OBJECTIVES: Economic evaluation (EE) estimates for individual centres in multi-
centre randomized controlled trials (RCTs) can differ significantly from the trial-
wide result. The existing methods addressing the generalisability of EE results from
RCTs (e.g. bivariate hierarchical modelling) assume that the recruiting centres are
representative for their jurisdictions, but this assumption has not been generally
verified. No explicit method of selecting centres and their recommended sample
sizes has been described, despite having been suggested in the literature.
METHODS: The working hypothesis is that transparent centre selection is a crucial
step in assessing the generalisability of EE results from RCTs. Two questions arise:
1) What criteria underpin the current practice of selecting centres for RCT-based
EEs? and 2) Can a valid quantitative algorithm be formulated to assist the centre
selection process at the trial design stage? RESULTS: First, the use of modelling-
based methods addressing generalisability has to be supported by evidence that
centres are representative for the jurisdiction under scrutiny. There is, thus, a need
to assess the current practice of selecting centres for RCT-based EEs. Second, a
quantitative methodology for purposively selecting centres for RCTs coupled with
EEs has to be devised in order to underpin an objective centre selection process.
The proposed operational measure is a generalisability index (GIx) which aggre-
gates relevant generic and intervention-specific covariates and can be formulated
at both jurisdiction and centre-level. The GIx can be validated against centre-level
cost-effectiveness estimates.CONCLUSIONS:A successfully validated GIx will pro-
vide evidence towards the legitimate use of existing generalisability techniques.
The GIx will allow an objective generalisability assessment for centres that did not
participate in the RCT. Describing the rationale for centre selection must become a
standalone item in reporting checklists for RCTs and EEs. Furthermore, such a
methodology will bridge policy and research by correlating jurisdictional interests
with RCT design.
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MULTIPLE CHOICES - HOW TO MAKE RATIONAL DECISIONS ACROSS SEVERAL
INTERVENTIONS WHEN FACED WITH DIFFERENT OUTCOMES AND
PERSPECTIVES?
Topachevskyi O1, Emerson R2, Standaert B1
1GlaxoSmithKline Biologicals, Wavre, Belgium, 2Emerson Consulting, Tervuren, Belgium
OBJECTIVES: In any assessment to facilitate decision making to allocate limited
funding across multiple innovations, the relative value of clinical outcomes or cost
containment depends upon preferences. In the case of allocating funds across a
portfolio of interventions, one could maximise cases-, hospitalizations-, or deaths-
avoided; and/or minimize costs from a health care payer or societal perspective.
The optimal mix of innovations to reach the preferred target can be investigated by
applying operational research modelling. However, a composite outcome is re-
quired in order to maximise multiple endpoints consecutively depending upon
preferences for different endpoints. METHODS: An optimization model was devel-
oped in Microsoft Excel® using the solver function to evaluate the optimal mix of
vaccines to implement within a portfolio, in order to avoid specific clinical out-
comes (GP-visits, hospitalisations, deaths) or maximise QALYs gained within spe-
cific constraints including budget. A composite endpoint was developed to take
into account different endpoints, clinical and cost, weighted according to prefer-
ences defined by the assessor. The composite endpoint was used as the objective
function. RESULTS: Depending upon the preference weights defined when deter-
mining the composite endpoint, the allocation of resources across a portfolio of
several vaccines resulted in different recommendations. If deaths-avoided was
weighted highest then the model would optimize on elderly influenza vaccination,
adolescent HPV and infant pneumococcal vaccines. If cases-avoided was the high-
est preference then varicella, rotavirus and pertussis vaccines were recommended.
If cost-offsets from a payer perspective were maximised then the recommendation
would be to first implement adolescent HPV, elderly influenza and rotavirus vac-
cination. The combination of preferences to avoid mortality and/or morbidity
and/or maximize cost offsets resulted in the recommendation to implement dif-
ferent vaccines from the portfolio.CONCLUSIONS:The use of a composite measure
and operational research modelling provides a tool to facilitate resource allocation
across a portfolio of interventions depending upon decision-maker preferences.
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THE ROLE OF THE INSTRUMENT DEVELOPER IN THE TRANSLATION OF
PATIENT REPORTED OUTCOME MEASURES
Clayson D, Verjee-Lorenz A, Miller F, Two R
PharmaQuest Ltd, Banbury, Oxfordshire, UK
OBJECTIVES: Developers of patient reported outcome (PRO) measures are often
involved in the translation of their measures into other languages, and they pro-
vide valuable guidance by reviewing concept elaboration and back translation re-
view documents and participating in harmonisation meetings. METHODS: How-
ever, many of the translation problems that they help resolve are due to difficulties
in translating concepts in the measure that are either culturally bound or idiomatic
to the source language, and these are features that might be addressed more ef-
fectively at an earlier stage. RESULTS: The developer can have a positive impact on
future translations right from the onset by considering the ‘translatability’ of con-
cepts when they are developing their conceptual model and generating their item
pool, thereby aiming to create a measure which can be translated more accurately.
CONCLUSIONS: We will examine common linguistic and cultural features which
may make measures difficult to translate, and how developers can avoid these to
help create global PRO measures that can be applied to all cultures and be admin-
istered in global clinical trials and health research.
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SHOULD WE AGGREGATE COST-EFFECTIVENESS OVER AN INTERVENTION’S
ENTIRE IMPLEMENTATION LIFETIME?
O’Mahony J
Erasmus University Medical Center, Rotterdam, The Netherlands
OBJECTIVES: Recent work has suggested that interventions’ cost-effectiveness
should be assessed over their entire lifetime of implementation, not just over the
period of use for a single cohort as typically modelled (Hoyle and Anderson, Med-
ical Decision Making, 2010; Hoyle, PharmacoEconomics, 2011). Such lifetime mod-
elling can capture changes in costs and effects over time. These changes in costs
and effects can result from price changes, disease dynamics or the application of
differential discounting of costs and health effects. METHODS: Suggesting cost-
effectiveness be assessed over an intervention’s complete lifetime carries assump-
tions regarding the nature of the decision problem in healthcare resource alloca-
tion. In particular, it suggests resources be allocated on the basis of the total cost-
effectiveness over all periods in which it is implemented. This lifetime perspective
can conflict with the alternative perspective that resources be allocated on the
basis of relative cost-effectiveness within each given period. We discuss a number
of simple theoretical examples in which the rank ordering of cost-effectiveness of
two interventions is different under the two perspectives. The examples include
when the prices of interventions trend and have different expected lifetimes, when
differential discounting is applied in certain circumstances, or simply when the
price of only one intervention falls following patent expiry. RESULTS: These exam-
ples prompt us to consider which perspective is more appropriate. We argue that as
health care resource allocation is an ongoing, repeated resource allocation prob-
lem, not one over a finite horizon, that the lifetime perspective is not appropriate.
CONCLUSION: Advances in decision analytic modelling need to carefully reflect the
actual nature of policy choices. The per-period perspective appears more appro-
priate to healthcare resource allocation problems than the total implementation
lifetime perspective. However, the actual resource allocation process is likely to
more complex than either perspective alone might suggest.
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COMPARISON OF RECONCILIATION AND REVIEW METHODOLOGIES FOR THE
TRANSLATION OF PATIENT REPORTED OUTCOME (PRO) MEASURES
Verjee-Lorenz A, Two R, Clayson D, Miller F
PharmaQuest Ltd, Banbury, Oxfordshire, UK Objective: The translation of patient reported
outcome (PRO) measures typically involves two key stages where the translation is created and
refined.
METHODS: The first is the reconciliation of two independent translations by an
in-country investigator (a lead translator). The second is the back translation re-
view - the reconciled translation is translated back into English and the project
manager reviews the English translation(s) against the source text, then the trans-
lation is refined through discussion between the project manager and the investi-
gator. Both stages are conducted via email, and the back translation review report
is usually reviewed by the instrument developer once all issues have been ad-
dressed. We will present an alternative methodology whereby the reconciliation
and back translation review are conducted through live conversations (in telecon-
ferences or otherwise) involving forward translators and the instrument developer.
RESULTS:We will compare these two processes in terms of the types of discussion
A432 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
and communication they enable. We will also look at the practicalities of each
method, and their relative merits and drawbacks and how these can be addressed
to maximise their usefulness in refining and improving the translation.
CONCLUSIONS: We will argue that both methods are beneficial in particular cir-
cumstances, and will explore the situations in which each one would be the most
appropriate.
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WHAT EPRO MODALITY IS APPROPRIATE FOR YOUR STUDY?
O’Gorman HJ1, Ross J2, Peck R2, Ross E2
1Almac Group, Craigavon, UK, 2Almac Clinical Technologies, Souderton, PA, USA
OBJECTIVES: To help clarify which ePRO modality (IVR, IWR, Handheld) is appro-
priate for specific studies through providing three examples of diary requirements
and appropriate modalities. Emphasize making this decision early in the planning
process.METHODS: Examples for three scenarios requiring patients to record their
PRO data electronically were drawn up based on experience to illustrate how mak-
ing appropriate modality choices can minimize patient burden and reduce costs.
Scenario One - 10,000 patient global vaccine study. Scenario Two – 500 patient
global study, daily diary having 40 questions with more than 5 response options.
Scenario Three – 50 GI patients to record their PRO data episodically using a VAS
scale daily for over a year. RESULTS: Scenario One – Appropriate Choice IVR: It is
expensive and logistically challenging for Sponsors to deploy 10,000 PDAs. Using
the IVR global network in place would reduce cost and logistics for the Sponsor and
sites. Scenario Two – Appropriate Choice IWR: When patients are provided more
than 5 response options in a lengthy questionnaire, an IWR would be better since
response options are visual. IWR would be better than PDA given the sample size
and logistics. Scenario Three- Appropriate Choice  PDA: A PDA would be most
convenient for the patient since they are providing data daily for over a year. PDA
is best for VAS scales since the size of the screen can be controlled. CONCLUSIONS:
There is overlap in deciding which ePRO modality to use for a particular clinical
study. It is critical to decide on the modality early when assembling the protocol, so
all points can be considered. Looking at the diary requirements (frequency, length,
access) for the study will help the Sponsor to decide which modality is best. Reduc-
ing patient and site burden will allow for greater compliance.
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OUTCOME MEASURES HIERARCHY FOR ATTENTION-DEFICIT HYPERACTIVITY
DISORDER
Hormaechea-Beldarrain JA1, Prieto L2
1Hospital Quiron Bizkaia, Erandio, Spain, 2London School of Hygiene and Tropical Medicine,
London, UK
OBJECTIVES: Attaining good patient health outcomes is the underlying purpose of
any health care intervention, including drug therapy. METHODS: The outcome
measure is the basis for evaluating the quality of health services, and a key element
in determining the value of health interventions since the value of health care is
defined as outcomes relative to cost. According to Porter (2010), value improvement
starts with defining and measuring the total set of outcomes for a medical condi-
tion and determining the major risk factors. Porter has provided a challenging
framework for identifying the full set of outcomes for any medical condition: the
outcome measures hierarchy (OMH). RESULTS:According to the OMH the full set of
outcomes for any medical condition, and its treatment, can be conveyed in a three-
tiered hierarchy. Each tier of the hierarchy contains two broad levels, each of which
involves one or more distinct outcome dimensions. Each medical condition should
have its own outcome measures. Measurement efforts should begin with at least
one outcome dimension at each tier, and ideally at each level. Possible outcome
dimensions for Attention-Deficit Hyperactivity Disorder (ADHD) are explored and
discussed according to Porter’s OMH. ADHD is a frequent neurobehavioral disorder
that is characterised by inattention, hyperactivity and impulsivity. ADHD is asso-
ciated with considerable social, family, behavioural and cognitive dysfunction, and
is comorbid to depression, bipolar disorder, anxiety, and drug use. Specific dimen-
sions proposed are aimed at capturing particular aspects of patients affected by
ADHD. For each dimension, success is measured with several clinical and patient
reported metrics. Tier 1 of the OMH is the patient’s health status achieved or
retained after a health intervention (clinical or drug therapy). CONCLUSIONS: Tier
2 regards the process of recovery and the eventual disutility of the treatment pro-
cess. Tier 3 concerns the sustainability of health.
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MEASURING RELATIVE EFFECTIVENESS IN EUROPE: AS IN THE USA, HERE TOO,
IT IS TIME TO TURN THE QALY PAGE
Prieto L
European Medicines Agency, London, UK
OBJECTIVES: The recently enacted Patient Protection and Affordable Care Act in
the United States of America (USA) has created a Patient-Centered Outcomes Re-
search Institute to conduct comparative effectiveness research, but has prohibited
this institute from developing or using cost-per-QALY thresholds. METHODS: In
reaction to this new legislation some authors, from both continents, have insisted
that QALYs provide a convenient yardstick for measuring and comparing health
outcomes of varied interventions across diverse diseases and conditions. Such
arguments in defense of QALYs are erroneous. While it is true that QALYs are
internationally recognized as the standard metric of the value of health outcomes,
this acknowledgement is, unfortunately, not deserved. RESULTS: The problem lies
in the QALY calculation (i.e. Utility x Time). While Time is expressed in a ratio scale
with a non-arbitrary zero value, Utility is defined as an interval scale with an
arbitrary zero point (i.e. death). Permissible arithmetic operations on interval
scales are limited: addition and subtraction are allowed, but multiplication and
division are not permitted because the absence of an absolute zero. Consequently,
the resulting QALY values are not expressed in the same units as the Time scale,
preventing any meaningful conclusion on its application to comparative clinical
effectiveness research. CONCLUSIONS: Although we do not know the exact rea-
sons why the Patient Protection and Affordable Care Act bans the use of cost per
QALY in the USA, the initiative should be celebrated, not criticized, and certainly
copied in Europe as well.
Cancer – Clinical Outcomes Studies
PCN1
BURDEN OF HOSPITALIZATION IN PATIENTS WITH ADVANCED LUNG CANCER
IN FRANCE AND GERMANY
Lobosco S1, Taylor-Stokes G1, Iyer S2
1Adelphi Real World, Cheshire, UK, 2Pfizer, New York, NY, USA
OBJECTIVES: To assess the burden of hospitalization in advanced lung cancer pa-
tients in France and Germany. METHODS: Oncologists (N80) and pulmonologists
(N40) actively involved in management of Non small cell lung cancer (NSCLC) in
France and Germany were invited to participate in a lung cancer disease specific
program. Each consenting physician was asked to complete patient record forms
for the next 10 advanced (stage IIIB/IV) lung cancer patients seen in their practice.
The study period extended from July to October 2010. Data on hospitalization over
the past year was provided by the physicians using the patient chart records. The
primary reason of hospitalization and the length of stay (LOS) were reported.
RESULTS: Majority of the patients (N1213) were male (68%), Caucasian (92%),
Stage IV (89%), currently on first line therapy (51%) with an average age of 63 years.
Hospitalization records were obtained for 93% (n1133) of the patients among
which 30% (n341) of the patients had one or more hospitalization events in the
previous year with an average (SD) LOS of 10 (8) days. The primary cause reported
for the 449 hospitalization events were disease symptoms (44%), surgery (20%) and
therapy side effects (17%). The LOS for surgery related hospitalization (n89)
ranged from 1-20 days (mean: 8 days). Among patients hospitalized for disease
symptoms (n197) the most frequently reported primary causes were dyspnea
(23%), cough (10%) and pain (11%) with average LOS of 13, 12 and 8 days respec-
tively. Among patients hospitalized for side effects (n75), anemia (24%), febrile
neutropenia (8%), febrile aplasia (8%) were most frequently reported with average
LOS of 4 days. CONCLUSIONS: Burden of hospitalization due to disease symptoms
and treatment related side effects is significant in France and Germany. Innovative
therapies effective in alleviation of symptoms and side effects could help signifi-
cantly in decreasing hospitalization costs.
PCN2
A RETROSPECTIVE LONGITUDINAL STUDY OF TREATMENT PATTERNS AND
OUTCOMES AMONG PATIENTS WITH UNRESECTABLE STAGE IIIC/IV
MELANOMA IN CANADA (MELODY)
Osenenko K1, Szabo SM1, Schultz M2, Mihalcioiu C3, Lane S1, Levy AR1
1Oxford Outcomes Ltd., Vancouver, BC, Canada, 2Bristol-Myers Squibb Canada, Montreal, QC,
Canada, 3McGill University, Montreal, QC, Canada
OBJECTIVES: Unresectable metastatic melanoma patients (stages IIIc/IV) have a
poor prognosis. Recent improvements in survival have been attributed in part to
earlier detection and investigational therapies, however melanoma is considered
incurable if it becomes metastatic. No information about treatment patterns for
unresectable melanoma in Canada has been published. Objectives of this study
were to describe disease characteristics, treatment patterns, health outcomes, and
resource utilization for Canadian unresectable melanoma patients treated outside
randomized clinical trials [RCT]. METHODS: Charts of melanoma patients at seven
Canadian centres were screened for eligibility. Unresectable melanoma charts
then selected consecutively in reverse chronological order from January 2009 until
target number (n250) exceeded. Data on patient and disease characteristics,
treatments (across three lines), adverse event management, health outcomes and
resource utilization were then extracted from charts of patients with at least two
months of follow-up, from diagnosis until censoring (June 2010 or death). RESULTS:
Of 1426 melanoma patient charts reviewed, 262 (18%) were for unresectable mela-
noma patients, 16% (43/262) of which were first diagnosed in an advanced stage.
Overall, 10% (26/262) participated in an RCT during the follow-up period and 60%
(156/262) received systemic therapy outside an RCT. In the latter group, responsive-
ness to therapy was low; only 20% (26/132) on first-line and 16% (9/58) on second-
line therapy experienced complete or partial response. On first-line therapy, 40%
(53/132) experienced adverse events requiring medical management and 18% (24/
132) were hospitalized during treatment; corresponding figures for second-line
were 38% (22/58) and 24% (14/58) respectively. CONCLUSIONS: This study charac-
terizes treatment patterns and provides quantitative estimates of resource utiliza-
tion for unresectable melanoma patients across Canada. Extant systemic treat-
ments are associated with poor response and considerable resource utilization.
This study quantifies the grim prognosis faced by advanced melanoma patients in
Canada receiving currently available treatments.
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CETUXIMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL
CANCER
Ubago R1, Castillo MA
1, Flores S2, Rodriguez R1, Beltran C1
1
Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Seville, Andalucia, Spain,
2Andalusian Agency for Health and Technology Assessment, Seville, Andalucia, Spain
OBJECTIVES: To evaluate the efficacy and safety of cetuximab in combination with
chemotherapy vs. chemotherapy alone for the first-line treatment of metastatic
colorectal cancer (mCRC), in patients with KRAS wild-type tumours. METHODS:
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